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Abstract
Drug transporters are becoming increasingly recognized as relevant to the drug development process. This may be a reflection of increasing target
complexity and the need for high-affinity interaction with drug targets that minimize off-target side effects. Moreover, as new molecular entities (NMEs)
become larger in size and amphipathic in nature, interaction with drug transporters, both uptake as well as efflux, becomes increasingly likely. In some
cases transporters may limit the absorption or organ-specific entry of NMEs, whereas in other cases transporters may enhance their absorption or
tissue accumulation. Indeed, in some cases, transporters may prove to be a therapeutic target. Accordingly, a better understanding of potentially clinically
relevant drug transporter polymorphisms earlier in the drug development process is highly desirable. In this review we examine key transporters that
are important to the absorption, distribution, and excretion of a large number of drugs in clinical use. Importantly, we provide our assessment of the
potential impact of known polymorphisms in such transporters and discuss whether there is sufficient evidence to incorporate these polymorphisms
in the drug development process.
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Transporters are proteins localized to the plasma
membrane and membranes of numerous subcellular
organelles that function to facilitate the uptake or
clearance of toxins, xenobiotics, and endogenous
molecules important for cellular homeostasis. Transporters are classified into 2 superfamilies based on
sequence homology: the ATP-binding cassette (ABC)
family and the solute carrier (SLC) family. ABC transporters function as efflux transporters that directly
harness energy produced by ATP hydrolysis. SLC transporters mediate import or, in some cases, export of
substrates via an ion gradient established by ATPdependent pumps or an electrochemical gradient.1 To
date, 48 ABC transporters and 350 SLC transporters
have been annotated in the human genome, and approximately 30 of these are involved in the disposition of
drugs.2,3 Moreover, membrane transporters located on
the intestinal epithelium, liver, and kidney modulate the
overall pharmacokinetic (PK) profiles of new molecular entities (NMEs) and are therefore important considerations in drug development. In addition, membrane
transporters expressed in organs that possess a barrier
function, such as the blood-brain barrier, have proved
to be highly relevant to drug development and therapeutic targeting.4 The locations of key transporters are
summarized in Figure 1.
The discovery and development of safe and effective NMEs require the consideration of multiple

factors that impact drug disposition. Indeed, until recently, genetic variation in drug-metabolizing enzymes
(DMEs) has been the major focus of pharmacogenetics. However, in the past decade, single nucleotide polymorphisms (SNPs) in membrane transporters have been demonstrated to be important, and
sometimes rate-limiting, determinants of drug disposition and response.5 Recognizing the need to evaluate
the impact of membrane transporters during the drug
development process, the International Transporter
Consortium (ITC) developed guidelines for assessing the importance of emerging key transporters in
drug development.4 Subsequently, in 2013, the Food
and Drug Administration (FDA) published a clinical
pharmacogenomics guidance titled, “Clinical Pharmacogenomics: Premarketing Evaluation in Early-Phase
Clinical Studies and Recommendations for Labeling.”
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Figure 1. Illustration of important efflux and uptake transporters in the (a) intestinal epithelia, (b) proximal tubule of the kidney, (c) liver, and (d) bloodbrain barrier that may be involved in the absorption, distribution, metabolism, and excretion of a drug. Abbreviations: ASBT, apical sodium-dependent
bile acid transporter;MCT,monocarboxylate transporter;OATP,organic anion-transporting polypeptide;PEPT,peptide transporter;BCRP,breast cancer
resistance protein; MDR, multidrug resistance; OCT, organic cation transporter; OST, organic solute transporter; OAT, organic anion transporter; MATE,
multiantimicrobial extrusion protein;URAT,urate transporter;OCTN,organic zwitterion/cation transporters;NTCP,Na+ -taurocholate cotransporting
polypeptide; BSEP, bile slat export pump. (Adapted from International Transporter Consortium.4 )

This work sought to provide more specific guidance to
the pharmaceutical industry with regard to genetic variants in both DMEs and membrane transporters and
emphasized the incorporation of pharmacogenomics
into the drug development process.
However, the field of drug transporters, particularly in relation to clinically relevant transporter polymorphisms, continues to evolve rapidly and merits
ongoing assessment to aid in future drug development. Although the definition of clinically significant
transporter polymorphisms remains debatable, based
on observed drug-drug interactions associated with
transporters, a 3-fold or higher increase in AUC of
transporter substrate drug would fit such a definition.
However, for many drugs in clinical use, clinical relevance may occur even at much lower AUC increase of

substrate drugs. Accordingly, in this review, we summarize the key drug transporter polymorphisms associated
with variations in drug pharmacokinetics and response.
Specifically, we focus on SNPs within members of
the organic cation transporters (OCTs), organic aniontransporting polypeptides (OATPs) family of SLC
transporters, in addition to multidrug-resistant proteins
(MRPs), breast cancer resistance protein (BCRP), and
P-glycoprotein (P-gp, MDR1, ABCB1).

SLC Transporter Polymorphisms of
Potential Clinical Significance
Organic Anion-Transporting Polypeptides
In humans, 12 organic anion-transporting polypeptides (OATP proteins; encoded by the SLCO gene
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family) have been identified with a wide substrate
specificity for amphipathic molecules, including endogenous compounds such as bile acids and hormones, and xenobiotic substrates including statins, antidiabetics, and chemotherapeutic agents.6,7 Of these,
OATP1B1 (SLCO1B1), OATP1B3 (SLCO1B3), and
OATP2B1 (SLCO2B1) are largely expressed at the
sinusoidal endothelium of the liver and mediate hepatocellular uptake of substrates from portal circulation;
OATP2B1 is also expressed on intestinal endothelia,
where it facilitates the absorption of its substrates.8
Interestingly, OATP1A2 (SLCO1A2) is expressed in the
distal nephron, apical membrane of cholangiocytes, ciliary body epithelium of the eye, and capillary endothelia of the brain and is now thought to facilitate brain
entry of certain medications.9 Select OATP variants
and their effects are summarized in Table 1.
OATP1B1. Of the 40+ nonsynonomous variants that
have been identified in human SLCO1B1, c.521T>C
(rs4149056) in exon 5, first identified by Tirona et
al, is the most extensively characterized.6,10 SLCO1B1
c.521T>C has an allele frequency of approximately 8%
to 20% in European individuals with lower frequencies
in East Asian and African-American individuals.11 In
vitro work suggests that the c.521T>C variant significantly impairs transport activity of several OATP1B1
substrates through reduced transporter expression at
the plasma membrane.10 Clinically, the significance
of SLCO1B1 c.521T>C is best exemplified by its
effects on statins. For example, the areas under the
plasma drug concentration-time curves (AUCs) for the
pharmacologically active form of simvastatin (simvastatin acid) were 120% and 221% higher in c.521C/C
healthy volunteers than in those with the c.521C/T and
c.521T/T genotypes, respectively.12 Furthermore, the
c.521T>C variant was strongly associated with the risk
for simvastatin-induced myopathy in a genome-wide association study (GWAS) that compared 85 patients with
myopathy on high-dose simvastatin with 90 matched
controls.13 These studies, in conjunction with others,
spurred the Clinical Pharmacogenetics Implementation
Consortium (CPIC) to include recommendations for
genotype-informed dosing of statins in the 2014 guideline update.14
Another commonly studied SNP in SLCO1B1
is c.388A>G (rs2306283), which has been shown
to cause increased liver OATP1B1 expression in a
white population.15 Allele frequencies for SLCO1B1
c.388A>G appear to range from 26% to 77% in
European and sub-Saharan individuals, respectively.11
Unlike c.521T>C, c.388A>G is associated with lower
plasma concentrations of various statins,16,17 and homozygous variant carriers have shown increased lowdensity lipoprotein (LDL) reduction in response to
atorvastatin treatment when compared with heterozy-
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gous and homozygous wild-type individuals.18 Interestingly, Teft et al found that although c.521C was
significantly associated with increased exposure to the
active metabolite of irinotecan, the progression-free
survival (PFS) was significantly longer in c.388G/G
advanced cancer patients treated with irinotecan-based
regimes.19 Moreover, c.521T>C and c.388A>G can
be in linkage disequilibrium and result in 4 functionally distinct haplotypes with varying effects on drug
disposition.8
OATP1B3. c.334T>G (rs4149117) and c.699G>A
(rs7311358) in SCLO1B3 are frequently observed
across diverse ethnic populations and have been shown
to alter the pharmacokinetics of certain medications.20
For example, both variants have been associated with
increased dose-adjusted AUC of the immunosuppressant mycophenolate mofetil (MMF) in Japanese renal
transplant patients.21 In contrast, Picard et al investigated MMF plasma exposure in kidney transplant patients who were coadministered tacrolimus or sirolimus
and found that carriers of at least 1 c.334T allele
had a 1.4-fold higher AUC than carriers of the GG
genotype.22 More recently, 334T>G has also been associated with increased imatinib clearance and increased
accumulation within the leukocytes in chronic myeloid
leukemia patients.23,24 Interestingly, inactivating mutations of SLCO1B1 and SLCO1B3 result in Rotor syndrome, a benign but very rare autosomal recessive liver
disease associated with conjugated hyperbilirubinemia,
impaired hepatic uptake of diagnostic dyes, and delayed
clearance of certain anionic drugs.25 Clinical impact of
SLCO1B3 genetic variation, particularly of relevance
to drug development, remains to be clarified.
OATP2B1. Compared to the extensive knowledge
on the clinical significance of polymorphisms in
SLCO1B1, data surrounding the functional consequences of SLCO2B1 polymorphisms are limited.
One of the first nonsynonymous variants described
in SLCO2B1 was c.1457C>T, which has an allele frequency of approximately 3% and 31% in
white and Asian individuals, respectively.8 Although
c.1457C>T does not appear to affect OATP2B1 protein expression,15 it has been linked to decreased
AUC of both celiprolol (β-blocker),26 and fexofenadine
(antihistamine) in healthy volunteers.27 In contrast,
Akamine et al found lower levels of S-fexofenadine
in healthy Japanese variant carriers following a 60-mg
dose of fexofenadine.28 Similarly, SLCO2B1 c.935G>A
(rs12422149) was associated with decreased plasma
concentrations of montelukast (leukotriene receptor
antagonist) and decreased symptom improvement in
asthma patients in 1 study,29 and another study
found no association between the variant and montelukast pharmacokinetics.30 These conflicting findings
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Table 1. Organic Anion-Transporting Polypeptides

Variant

Effect on
mRNA/Protein

Drug Class

In Vitro/ In Vivo

Select Variants and Variant Effects Within SLCO1A2 (OATP1A2)
I13T, 38T>C
Antimetabolites
In vitro
rs10841795
Tyrosine kinase
In vivo
inhibitors

Q172D, 516A>C
rs11568563

Variant appears to
cause a reduction
in cell surface
transporter
expression9

–1105G>A
rs4148977
–1032G>A
rs4148978
–361G>A
rs3764043

Low/Preliminary

Tyrosine kinase
inhibitors

In vitro

Imatinib: ↓ uptake (HeLa cells)32

In vivo

Imatinib: No effect on drug
levels in white cancer patients
(n = 94)32
Imatinib: ↓ clearance in CML
patients (n = 34)33
Imatinib: ↓ clearance in CML
patients (n = 34)33
Imatinib: ↑ clearance in CML
patients (n = 34)33

In vivo
In vivo
In vivo

In vitro
In vivo

Variant causes
increased liver
protein expression
in white
population15

Low/Preliminary

In vitro

Tyrosine kinase
inhibitors
Tyrosine kinase
inhibitors
Tyrosine kinase
inhibitors

Meglitinides

In vivo

Antimetabolites

In vivo

Alkaloids

In vivo

Statins

In vivo

In vivo

Drug/Effect
Associationa

Methotrexate: ↑ uptake
(Xenopus laevis oocytes)104
Imatinib: No effect on average
steady-state concentration in
white cancer patients
(n = 94)32
Deltorphin II and
[D-penicillamine-2,5]enkephalin (DPDE): ↓
uptake (HeLa cells)31

δ-Opioid receptor
agonists

Select Variants and Variant Effects Within SLCO1B1 (OATP1B1)
V174A, 521T>C
Variant causes
Statins
In vivo
rs4149056
reduced
membrane
transporter
expression10
In vivo

N130D, 388A>G
rs2306283

Allele Effect/Association

Low/Preliminary

Low/Preliminary

Low/Preliminary
Low/Preliminary
Low/Preliminary

Simvastatin Acid: ↑ AUC and
Cmax (n=32);105 variant
strongly associated with ↑
simvastatin-induced myopathy
risk (n = 175)13
Pravastatin: ↑ drug plasma
concentration in healthy white
volunteers (n = 41)106
Pravastatin: ↓ Vmax (HEK 293
cells)107
Atorvastatin and
Rosuvastatin: ↑ AUC in
healthy volunteers (n = 32)108
Repaglinide: ↑ AUC in both
homozygous and heterozygous
variant carriers when
compared to wild-type
individuals (n = 56)109
Methotrexate: ↓ clearance in
children diagnosed with acute
lymphoblastic leukaemia
(n = 434)110
Irinotecan: ↑ plasma exposure
of active metabolite in
advanced cancer patients
(n = 127)19
Pravastatin: ↓ AUC in healthy
Japanese volunteers (n = 23)16

High

Atorvastatin: ↑ LDL reduction
for GG variant carriers when
compared with GA and AA
carriers (n=136)18

Low/Preliminary

Moderate

Moderate

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

(Continued)
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Table 1. Continued

Variant

Effect on
mRNA/Protein

Drug Class

Allele Effect/Association

In vivo

Lovastatin Acid: ↓ AUC in
healthy white volunteers
(n = 27)17
Irinotecan: ↑ PFS in advanced
cancer patients
(n = 103)19
Ezetimibe: gene dose ↓ in AUC
in healthy volunteers
(n = 17)111
Repaglinide: ↓ AUC and Cmax ,
and ↑ mean blood glucose
concentration in healthy
volunteers (n = 8)112
Rifampin: ↓ AUC in adults with
pulmonary tuberculosis from
Africa, North America, and
Spain (n = 72)113
Pravastatin: heterozygous
carriers have a 98% ↑ drug
plasma concentration than
homozygous wild-type
individuals in healthy white
volunteers (n = 41)106
Irinotecan: ↑ AUC of active
metabolite in Korean patients
with advanced non-small-cell
lung cancer (n = 81)114

Low/Preliminary

Mycophenolate mofetil: ↑
dose-adjusted AUC and ↓ oral
clearance in Japanese renal
transplant recipients (n =
87)21 ; in contrast, a study in
kidney transplant patients
found ↓ plasma concentrations
(n = 70)22
Imatinib: ↑ clearance in Japanese
CML patients (n = 34)24
Imatinib: ↑ intracellular
accumulation in leukocytes of
CML patients (n = 15)23
Mycophenolate mofetil: ↑
dose-adjusted AUC and ↓ oral
clearance in Japanese renal
transplant recipients (n = 87)21
Docetaxel: ↑ AUC, ↓ oral
clearance, and ↑ risk of
docetaxel-induced adverse
events in Japanese cancer
patients (n = 84)116

Low/Preliminary

Montelukast: ↓ plasma
concentrations and ↓ symptom
improvement in asthma
patients (n = 489)29 ; in
contrast, a study done in
healthy volunteers found no
association between the variant
and montelukast
pharmacokinetics (n = 16)30

Low/Preliminary

Alkaloids

In vivo

Cholesterol
absorption
inhibitors
Meglitinides

In vivo

P155T, 463C>A
rs11045819

Antimycobacterials

In vivo

–11187G>A ,
rs4149015

Statins

In vivo

Alkaloids

In vivo

In vivo

Select Variants and Variant Effects Within SLCO1B3 (OATP1B3)
Immune
In vivo
S112A, 334T>G
Does not alter
suppressants
rs4149117
membrane protein
localization115

Tyrosine kinase
inhibitors

Drug/Effect
Associationa

In Vitro/ In Vivo

In vivo
In vivo

M233I, 699G>A
rs7311358

Does not alter
membrane protein
localization115

Immune
suppressants

In vivo

IVS12-5676A>G
rs11045585

Does not affect
protein
expression15

Mitotic inhibitors

In vivo

Select Variants and Variant Effects Within SLCO2B1 (OATP2B1)
Leukotriene
In vivo
R312Q, 935G>A
Variant does not
receptor
rs12422149
appear to affect
antagonists
protein
expression15

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

Moderate

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

(Continued)
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Table 1. Continued

Variant

S486F, 1457C>T
rs2306168

Effect on
mRNA/Protein

Variant does not
appear to affect
protein
expression15

Drug Class

In Vitro/ In Vivo

Allele Effect/Association

In vitro

Montelukast: ↓ transport
(Caco-2 cells)29
Celiprolol: ↓ AUC in healthy
participants (n = 30)26

β-Blockers

In vivo

Antihistamine

In vivo

Fexofenadine: ↓ AUC in healthy
individuals (n = 14) 27 ; in
contrast, the variant was
associated with ↑ AUC of
S-fexofenadine in healthy
Japanese volunteers (n = 24)28

Drug/Effect
Associationa

Low/Preliminary

Low/Preliminary

a
High: annotation for a variant-drug combination where most evidence demonstrates an association. The association must be replicated in more than 1 cohort
with significant P-values. Moderate: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated
in more than 1 cohort, but there may be some studies that do not show statistical significance. Low/Preliminary: annotation for a variant-drug combination
based on a single significant study or annotation for a variant-drug combination evaluated in multiple cohorts but lacking clear evidence of an association; this
classification also encompasses associations that have been studied only in vitro.

underscore the need for further investigations into
SLCO2B1 polymorphisms and their effects on drug
disposition. Current knowledge does not support a
major role of SLCO2B1 SNPs in drug disposition;
thus, a major focus on SLCO2B1 genetic variation
during development is unlikely to more fully predict
clinical drug response or variation in the PK profile of
a OATP2B1 substrate NME.
OATP1A2. To date, OATP1A2 has been the only human OATP transporter detected in the brain capillary
endothelium and thus has the potential to play a role
in the central nervous system penetration of certain
medications.31 Our group had demonstrated decreased
transport of δ-opioid receptor agonists (deltorphin
II and [D-penicillamine-2,5]-enkephalin, DPDE) in
HeLa cells expressing the SLCO1A2 variant c.516A>C
(rs11568563).31 SLCO1A2 c.516A>C has an allele
frequency of approximately 2% and 5% to 7% in
African and white individuals, respectively, and appears to cause a reduction in cell surface transporter
expression.8,9 The effects of SLCO1A2 c.516A>C have
also been investigated in relation to imatinib (a tyrosine
kinase inhibitor) pharmacokinetics. However, a significant change in imatinib plasma concentrations in 94
white cancer patients was not observed.32 Interestingly,
another study found that common promoter polymorphisms in SLCO1A2 were associated with decreased
(c.–361G>A, rs3764043) and increased (c.–1105G>A,
rs4148977; c.–1032G>A, rs4148978) clearance of imatinib in Japanese myeloid leukemia patients.33 Taken
together, although OATP1A2 is likely to play an important role in the CNS entry of certain drugs, there is no
compelling evidence to suggest functional SNPs in this
transporter will have a major impact on substrate drug
response, particularly in terms of PK.

In general, among the SLCO variants, the SLCO1B1
variants c.521T>C and –11187G>A appear to have the
greatest evidence in support of their impact on statin
PK and toxicity profiles.
Organic Cation Transporters
The organic cation transporters (OCTs) belong to the
SLC22 family.34 In humans, the members of this subgroup include OCT1 (SLC22A1), OCT2 (SLC22A2),
and OCT3 (SLC22A3). These proteins share a very similar structure and translocate a number of endogenous
and exogenous substrates bidirectionally across cellular
membranes, primarily through facilitated diffusion.35,36
OCT1 is predominantly expressed on the hepatocyte
sinusoidal membrane, whereas OCT2 is positioned
mainly within the proximal tubule of the kidney, and
OCT3 is more broadly distributed.35,37 The OCTs have
been implicated in regulating the disposition of numerous drugs including metformin, lamivudine, and
numerous chemotherapeutics.35
A number of SNPs in the genes encoding OCT1
and OCT2 have been identified and are associated
with changes in the mRNA or protein expression of
these transporters.38–42 Furthermore, many of these
variants appear to be associated with reduced protein
and/or mRNA expression resulting in changes in the
in vitro and in vivo PK of biguanides, tyrosine kinase
inhibitors, and dopamine precursors (Table 2).
OCT1. In vitro work using HEK293 cells transfected with either SLC22A1 p.M420del (rs35191146)43
or SLC22A1 c.181C>T (rs12208357)44 has demonstrated decreased uptake of metformin, a bloodglucose-lowering medication that exerts its effect
by increasing peripheral insulin sensitivity.45 Moreover, healthy volunteer data have demonstrated that
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Table 2. Organic Cation Transporters

Variant

Effect on
mRNA/Protein

Drug Class

Select Variants and Variant Effects Within SLC22A1 (OCT1)
Tyrosine kinase
M420del, 1258delG
↓ protein expression
inhibitors
rs35191146
despite no
difference in the
amount of mRNA
transcript39

M408V, 1222A>G
rs628031

↓ hepatic protein
expression;
no association with
mRNA
expression38,49

In Vitro/ In Vivo

Allele Effect/Association

In vivo

Imatinib: ↑ probability of
treatment failure in chronic
myeloid leukemia patients
(n = 336)39

In vitro

Imatinib: ↓ uptake, but this
effect was countered if the
M408V (rs628031) SNP was
also present (KCL22-hOCT1
cells)39
Metformin: ↓ uptake and ↑
sensitivity to metformin
transport inhibition by
medications such
as verapamil and
amitriptyline (HEK293
cells)43
Imatinib: ↓ treatment
response, 5-year survival, and
event-free survival in chronic
myeloid leukemia patients
(n = 167)48
Metformin: positive predictor
of hematological, cytogenic,
and major molecular
responses in patients with
type 2 diabetes (n =33)49 ;
variant was not associated
with glucose or lipid control
in patients with type 2
diabetes (n = 135)50
Metformin: no change in
uptake (HEK293 cells)43
Metformin: ↑ AUC and Cmax
in healthy white volunteers44 ;
another study found no
association between the
variant and metformin
pharmacokinetics in patients
with type 2 diabetes
(n = 120), healthy white
individuals (n = 16), or
healthy Malaysian individuals
(n = 169)46
Metformin: ↓ uptake
(HEK293 calls)42
Metformin: ↓ efficacy in white
(n = 102)51 and South Indian
(n = 122)117 patients with
type 2 diabetes
Levodopa: ↑ doses and ↑
mortality in Parkinson
patients (n = 99)118
Imatinib: ↓ in apparent drug
clearance in chronic myeloid
leukemia patients carrying at
least 1 polymorphic allele
(n = 60)119

Biguanides

In vitro

Tyrosine kinase
inhibitors

In vivo

Biguanides

In vivo

In vitro
R61C, 181C>T
rs12208357

↓ protein expression
and membrane
localization40,42

Biguanides

In vivo

In vitro
1386C>A
rs622342

F160L, 480C>G
rs683369

No association with
altered mRNA
expression38

Biguanides

In vivo

Dopamine
Precursor

In vivo

Tyrosine kinase
inhibitors

In vivo

Drug/Effect
Associationa

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

Moderate

Low/Preliminary

Low/Preliminary

(Continued)
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Variant

Effect on
mRNA/Protein

Drug Class

Select Variants and Variant Effects Within SLC22A2 (OCT2)
Alkylating agents
A270S, 808G>T
Inconclusive data
rs316019
regarding changes in
protein expression;
variant may alter
substrate
recognition and
translocation47,120,121

Biguanides

In Vitro/ In Vivo

Allele Effect/Association

In vivo

Cisplatin: no association
between variant and
pharmacokinetic parameters
in white cancer patients (n =
106)122 ; variant was found to
be protective against
cisplatin-induced ototoxicity
in 64 pediatric patients and
66 adult patients123 ; variant
was found to be protective
against nephrotoxicity in
cancer patients (n = 53)124
Metformin: ↑ AUC/Cmax and
↓ renal clearance in healthy
Korean individuals (n =
26)54 ; variant associated with
↓ renal clearance in healthy
white and African-American
individuals (n = 23)120
Metformin: ↓ uptake
(oocytes)53

In vivo

In vitro

Drug/Effect
Associationa

Low/Preliminary

Low/Preliminary

a
High: annotation for a variant-drug combination where most evidence demonstrates an association. The association must be replicated in more than 1 cohort
with significant P-values. Moderate: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated
in more than 1 cohort, but there may be some studies that do not show statistical significance. Low/Preliminary: annotation for a variant-drug combination
based on a single significant study or annotation for a variant-drug combination evaluated in multiple cohorts but lacking clear evidence of an association; this
classification also encompasses associations that have been studied only in vitro.

individuals carrying a reduced-function SLC22A1
c.181C>T allele had an increased AUC and higher
maximum plasma concentration of metformin compared to those homozygous wild-type individuals;44
however, patient data did not replicate these findings.46
The prevalence of these 2 polymorphisms is variable depending on the ethnic group being evaluated. SLC22A1
p.M420del is more commonly seen in white (18.5%) and
Mexican (21.4%) Americans than in African Americans
(2.9%), whereas c.181C>T is less prevalent with frequencies of 7.2% and 5.6% for white and Mexican
Americans, respectively.47 Furthermore, the presence
of variant SLC22A1 p.M420del in KCL22-hOCT1
cells was also associated with reduced imatinib uptake,
although the effect was obliterated in the presence of
SLC22A1 c.1222A>G (rs628031).39 This effect translated to findings in imatinib-treated chronic myeloid
leukemia (CML) patients, where an increased risk of
treatment failure was seen in those carrying the variant
allele.48
SLC22A1 c.1222A>G (rs628031) is found in 74% of
African American, 60% of white American, and 74% to
80% of Asian individuals.47 Although in vitro studies
did not correlate with reduced uptake of metformin
in transfected HEK293 cells,43 a small study in 33
patients with type 2 diabetes on metformin revealed

that the variant allele was a positive predictor of
metformin efficacy.49 This finding was not supported
by a larger, more recent patient-based study, which
showed that the SLC22A1 variant c.122A>G did not
correlate with blood glucose levels or lipid control in
135 diabetic subjects.50 Additionally, a fourth SLC22A1
variant, c.1386C>A (rs622342), has been associated
with reduced metformin efficacy in white51 and south
Indian diabetic patients.52
OCT2. In comparison to SLC22A1, few variants
within SLC22A2 have been assessed for drug associations. However, SLC22A2 c.808G>T (rs316019), which
has an overall prevalence of approximately 7% to
16%,47 has been associated with decreased metformin
transport in vitro.53 Moreover, Song et al determined
that the SLC22A2 c.808G>T variant was associated
with increased metformin AUC and decreased renal
clearance in healthy Korean individuals.54 However,
this association has yet to be validated in a patient
population.
Overall, there is sufficient evidence to suggest that
a number of commonly occurring SNPs in SLC22A1
should be considered early in the drug development
process, when an NME is deemed to be a substrate of
this transporter. However, evidence does not suggest
appreciable drug-variant associations for OCT2.
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Overall, our understanding of the impact of genetic
variation in the OCTs is still in its infancy, with only
preliminary or single-study evidence available in most
cases. The exception appears to be the SLC22A1 variant
1386C>A, which appears to have a moderate association with metformin efficacy.

Efflux Transporter Polymorphisms of
Potential Clinical Significance
P-Glycoprotein
P-Glycoprotein (P-gp) is highly studied in drug development because of its widely appreciated capability for mediating the efflux transport of a broad
array of structurally divergent endogenous and xenobiotic compounds.55 P-gp substrates include various
antiepileptics, statins, selective estrogen receptor modulators (SERMs), protease inhibitors, and a number of
chemotherapeutic agents and immunosuppressants.56
The genetic variability of MDR1 has been extensively studied in vivo and in vitro, and a number of
MDR1 SNPs have been identified (Table 3).57 Most notably, nonsynonymous SNPs in exons 12 (c.1236C>T),
21 (g.2677G>T), and 26 (c.3435C>T) have been researched extensively with regard to their impact on P-gp
substrate pharmacokinetics.58 Although not shown in
vitro, of 15 identified MDR1 SNPs, Groups have
linked homozygous variant carriers of c.3435T to reduced P-gp tissue expression and higher drug plasma
concentrations.58,59 Moreover, several groups have
shown that c.3435C>T, g.2677G>T, and c.1236C>T
are inherited in linkage disequilibrium.60,61
Not all substrates of P-gp are impacted by genetic variation in MDR1. Hoffmeyer et al showed
an increase in digoxin plasma concentrations in individuals homozygous for the MDR1 c.3435T variant,
but this has not been replicated in other studies.56,58
The effect of the MDR1 c.3435C>T SNP on the
efficacy of antiepileptics such as carbamazepine has
been extensively reviewed. Although 1 systematic review of 4269 Chinese adult patients revealed an association between the CC genotype and anti-epileptic
resistance, similar reviews in larger and more diverse populations have failed to show any association
between MDR1 c.3435C>T and antiepileptic drug
response.62–64
Limited data exist regarding the effect of MDR1
polymorphisms on statin pharmacokinetics and patient drug response. Homozygous variant carriers of
MDR1 c.3435C>T and g.2677G>T have both been
linked to increased statin exposure and reduced statin
effect. Both the AUC and maximum concentrations of
pivastatin and rosuvastatin were increased in healthy
Chinese volunteers with the MDR1 g.2677TT and
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c.3435TT genotypes, respectively.65,66 Similarly, a small
study in Bosnian volunteers found a smaller statin
effect in individuals homozygous for the c.3435T
variant.67
The P2y12 inhibitor clopidogrel has been shown to
be a substrate of P-gp in vitro, and its oral absorption is affected by the inhibition or upregulation of
P-gp.68 The MDR1 c.3435C>T SNP has been shown to
modulate the pharmacokinetics and efficacy in multiple
patient cohorts; however, the findings were contradictory to the posited physiologic effect of the variant.
In a group of 60 white acute coronary syndrome
(ACS) patients, individuals with the TT genotype had a
lower clopidogrel AUC and maximal concentration.68
This was duplicated in a group of 401 Chinese ACS
patients, where the c.3435T variant was associated with
lower plasma concentrations of both clopidogrel and
its active metabolite and resulted in reduced platelet
inhibition.69
All 3 exonic SNPs, MDR1 c.3435C>T, c.1236C>T,
and g.2677G>T, have been linked to changes in protease inhibitor pharmacokinetics and effect, although
the evidence is not robust. In vitro, HEK293T cells
carrying the g.2677T variant did not transport telaprevir, and higher telaprevir trough plasma concentrations
were seen among 29 hepatitis C patients carrying a
variant allele.70 A Brazilian study of 187 HIV patients, among whom 27 were protease inhibitor nonresponders, were assessed for their MDR1 c.3435C>T
genotype. Conversely, individuals carrying the c.3435T
variant were more likely to fail first-line HIV treatment regimens compared to those carrying a wild-type
allele.71
Moreover, the immunosuppressants and chemotherapeutics cyclosporine, methotrexate, and imantinib
have been shown to be affected by genetic variation in
MDR1. Renal transplant patients homozygous for the
MDR1 c.3435T or the g.2677T variant had higher cyclosporine trough plasma concentrations compared to
individuals carrying a wild-type allele.72 In a small Korean population of post–stem-cell-transplant patients,
individuals carrying 2 variant MDR1 c.3435T alleles
had lower methotrexate clearance.73 Similarly, a small
Spanish cohort showed that the MDR1 c.34335CC
genotype was associated with primary failure of imantinib treatment in CML.74 A larger Chinese metaanalysis contradictorily found that the MDR1 c.1236T
variant was a possible risk factor for nonoptimal clinical response to imantinib treatment in Asian patients
with CML.75
Overall, although the c.3435T variant appears to
be linked to digoxin and chemotherapeutic pharmacokinetics, the evidence for other MDR1 variant-drug
associations needs more study in larger cohorts.
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Table 3. P-Glycoprotein

Variant

Effect on
mRNA/Protein

Drug Class

Select Variants and Variant Effects Within MDR1 (P-gp)
Glycosides
3435C>T
↓ duodenal protein
rs1045642
expression58
Antiepileptics

S893A/T,
2677G>T/A
rs2032582

1236C>T
rs1128503

In Vitro/In
Vivo

In vivo
In vivo

HMG-CoA reductase
inhibitors

In vivo

P2y12 inhibitor

In vivo

Glucocorticoid

In vivo

Protease inhibitors

In vivo

Antimetabolites

In vivo

Tyrosine kinase
inhibitors

In vivo

Protease inhibitors

In vivo

Immune suppressant

In vivo

Behavior modifier

In vivo

HMG-CoA reductase
inhibitors
Protease inhibitors

In vivo

Tyrosine kinase
inhibitors

In vivo

In vivo

Allele Effect/Association
Digoxin: ↑ AUC in healthy white
volunteers (n = 21)58
Multiple AEDs: CC genotype
associated with drug resistance
in a Chinese population
(n = 4269)63
Simvastain and Atorvastatin: ↓
benefit of statin therapy in
dyslipidemic patients (n =
180)67
Clopiogrel: ↓ AUC in patients
with acute coronary syndrome
(n = 401)69
Prednisone: variant associated
with ↑ risk for steroid-induced
osteonecrosis of the femoral
head in Chinese population
(n = 200)125
Multiple Protease
Inhibitors: variant associated
with ↑ failure of first-line
regimes in Brazilian HIV-infected
patients (n = 187)71
Methotrexate: ↓ clearance in
Korean patients after
hematopoietic stem cell
transplantation (n = 20)73
Imatinib: CC genotype associated
with primary failure in chronic
myeloid leukemia patients
(n = 65)74
Telprevir: ↑ trough
concentrations in hepatitis C
patients (n = 29)70
Cyclosporine: ↑ trough
concentrations in TT vs GG/GT
renal transplant recipients
(n = 101)72
OROS-methylphenidate: TT
genotype found to be an
independent determinant of
adverse drug reactions in
children with attention-deficit
hyperactivity disorder (n =
134)126
Pivastatin: ↑ AUC and Cmax in
non-G carriers (n = 12)66
Telprevir: ↑ trough
concentrations in hepatitis C
patients (n = 29)70
Imatinib: T variant associated
with nonoptimal clinical
response in Asian chronic
myeloid leukemia patients
(meta-analysis)75

Drug/Effect
Associationa

Moderate
Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

Moderate

Moderate

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary

Low/Preliminary
Low/Preliminary

Moderate

a
High: annotation for a variant-drug combination where most evidence demonstrates an association. The association must be replicated in more than 1 cohort
with significant P-values. Moderate: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated
in more than 1 cohort, but there may be some studies that do not show statistical significance. Low/Preliminary: annotation for a variant-drug combination
based on a single significant study or annotation for a variant-drug combination evaluated in multiple cohorts but lacking clear evidence of an association. This
classification also encompasses associations that have been studied only in vitro.
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The Multidrug Resistance Proteins MRP2, MRP3, and
MRP4
Common genetic variants in ABCC2 (MRP2), ABCC3
(MRP3), and ABCC4 (MRP4) have been linked to
changes in mRNA and/or protein expression as well to
changes in the disposition of many drugs in vivo including statins and antimetabolites such as methotrexate
and azathiopine/6-mp (Table 4). However, genetic variation within ABCC2 is most widely studied. This may
be due, in part, to the propensity of ABCC2 to tolerate
major loss of function with genetic variation. Indeed,
complete loss of MRP2 function is the molecular basis
for Dubin-Johnson syndrome.76
Interestingly, ABCC2 c.1249G>A (rs2273697) is
associated with reduced mRNA expression in human placenta but increased mRNA expression in human liver.77,78 ABCC2 c.1249G>A is found in 9% of
Asian, 22% of sub-Saharan African, and 24% of white
individuals.79 Conversely, ABCC2 variant, rs717620 is
associated with reduced ABCC2 mRNA in healthy kidney but not in liver or intestine, and variant rs4793665 is
associated with reduced ABCC3 mRNA expression in
liver tissue samples.77,80 The frequency of these variants
is 20% in Asian, white, and African populations for
the former and 56% to 86% across these groups for the
latter.81,82
Genetic variations in ABCC2 and ABCC4 have been
linked to alterations in methotrexate pharmacokinetics
and efficacy. Specifically, ABCC2 variants c.1249G>A
(rs2273697) and c.3972C>T (rs3740066) were associated with an increased risk of gastrointestinal toxicity
such as nausea and vomiting as well as hepatotoxicity
in a cohort of 65 children suffering from acute lymphoblastic leukemia (ALL).83 Similarly, in a cohort of
112 Chinese children with ALL, the ABCC2 variant
c.–24C>T (rs717620) was associated with increased
plasma concentrations as well as an increased risk of
clinical adverse drug reactions.84 The ABCC4 variant
c.1372A>C (rs9516519) is also associated with elevated
methotrexate plasma concentrations as well as drug
toxicity in children suffering from ALL.85
Taken together, SNPs in ABCC2 and possibly
ABCC4 should be considered as potentially relevant
during the drug development process if these transporters are considered to be essential or rate limiting
to the elimination of a NME in development.
Breast Cancer Resistance Protein
This efflux transporter, encoded by ABCG2 gene, is an
ATP-binding cassette efflux half transporter that likely
functions as a homodimer.4 Similar to P-glycoprotein,
breast cancer resistance protein (BCRP) appears to
serve as a barrier to limit the absorption, entry, or retention of diverse substrates including both endogenous
(eg, dietary flavonoids, porphyrins, estrone 3-sulfate)
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and exogenous (eg, statins, antineoplastics) molecules
into various tissue compartments.86
Pharmacogenetic studies have identified a number
of common SNPs in ABCG2 that are associated with
changes in the PK parameters for medications (Table 5).
Among the SNPs identified to date, a nonsynonymous
SNP c.421C>A (rs22331142) in exon 5 of BCRP, which
results in a glutamine-to-lysine change at amino acid
position 141, is the most extensively studied.87 ABCG2
c.421C>A has an allele frequency of approximately
10% with higher frequencies in Asian individuals and
lower frequencies in sub-Sahra African and AfricanAmerican individuals.88,89 In vitro work suggests that
the c.421C>A variant impairs protein expression by
30% to 40% but maintains mRNA expression when
compared with wild-type controls.90 Reduced BCRP
expression is possibly due to enhanced susceptibility
to ubiquitin-mediated proteasomal degradation and
incomplete trafficking to the plasma membrane.91,92
Carriers of the c.421C>A polymorphism have
demonstrated increased bioavailability of marketed
BCRP substrates. For example, the AUC for atorvastatin and fluvastatin were 72% greater, for simvastatin
lactone 111% greater, and for rosuvastatin 144% greater
in ABCG2 c.421A/A individuals than in c.421C/C
individuals.93,94 Furthermore, the ABCG2 c.421C>A
variant has been found to correlate in a gene-dose–
dependent manner with reductions in LDL cholesterol in individuals taking rosuvastatin to manage
their hypercholesterolemia.95,96 The c.421C>A polymorphism also appears to impact the disposition and
efficacy of antineoplastic medications. For example,
Sparreboom et al determined that heterozygous cancer
patients receiving a 20-minute infusion of diflomotecan
had significantly higher plasma concentrations of the
medication when compared to homozygous wild-type
individuals.97 Similar effects were also seen in vitro
for another topoisomerase inhibitor, topotecan, where
expression of the variant was associated with 30%
reduction in efflux transport of topotecan in HEK293
cells when compared to wild type.98 Similarly, ABCG2
c.421C>A has also been associated with increased
accumulation of imatinib, a tyrosine kinase inhibitor, in
HEK293 cells.99 More recently, Koo et al investigated
the 5-year PFS rate in 209 gastrointestinal stromal
tumor patients being treated with imatinib and found
that PFS was vastly superior in AA-carrying individuals when compared with patients carrying the CC or
CA genotypes.100 Interestingly, another recent study
suggested that ABCG2 c.421C>A polymorphism may
affect substrate distribution to the brain, as the mean
cerebrospinal fluid concentration of raltegravir, an antiHIV medication, was significantly lower among AA
and CA patients when compared with those individuals
with the CC genotype.101
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Table 4. Multidrug-Resistant Proteins

Variant

Effect on
mRNA/Protein

Drug Class

In Vitro/ In
Vivo

Allele Effect/Association

Drug/Effect
Associationa

Select variants and variant effects within ABCC2 (MRP2)
Antimetabolites
V417I, 1249G>A
Variant associated
rs2273697
with reduced
mRNA expression
in human preterm
placenta78 and
associated with
increased mRNA
expression in
human hepatic
tissue77
Antiepileptics

In vivo

Methotrexate: variant
associated with ↑ GI toxicity
in children with acute
lymphoblastic leukemia
(n = 65)83

Low/Preliminary

In vivo

Low/Preliminary

Antimetabolites

In vivo

Multiple antiepileptics:
meta-analysis indicated that
the variant genotypes (in
Asian or white populations)
were associated with a
significantly ↓ risk of
antiepileptic resistance127 ; no
association between the
variant and antiepileptic
response was found in
Croatian epilepsy patients
(n = 97)128
Methotrexate: ↑ plasma
concentrations ↑ risk of
hematologic and
nonhematologic adverse
events in Chinese children
with acute lymphoblastic
leukemia (n = 112)84

Statins

In vivo

Low/Preliminary

Antimetabolites

In vivo

Simvastatin and
atorvastatin: variant
associated with a dose ↓ or
switches to other
cholesterol-lowering drugs in
simvastatin, but not
atorvastatin, users
(n = 1014)131
Methotrexate: variant
associated with ↑
hepatotoxicity in children
with acute lymphoblastic
leukemia (n = 65)83

In vivo

Morphine: associated with ↓
levels of
morphine-6-glucoronide and
morphine-3-glucoronide in
children undergoing
outpatient
adenotonsillectomy
(n = 220)133

Low/Preliminary

In vivo

Azathioprine/6-MP: ↑
hematopoitic toxicity in IBD
patients (n = 235)135
Cyclophosphamide: ↑
adverse drug reactions (ie,
gastrointestinal toxicity and
leukopenia/neutropenia) in
403 breast cancer patients136

Low/Preliminary

–24C>T rs717620

I1324I, 3972C>T
rs3740066

Variant associated
with lower
ABCC2 mRNA
levels in the
normal human
kidney129 but not
in the intestine130
or liver77

Select Variants and Variant Effects Within ABCC3 (MRP3)
Opiates
–211C>T
Lower mRNA
rs4793665
expression in liver
samples81,132

Select Variants and Variant Effects Within ABCC4 (MRP4)
Immune suppressants/
E857K, 2269G>A
Impaired membrane
antimetabolites
rs3765534
localization134
3225+1243C>A
rs9561778

Alkylating agents

In vivo

Low/Preliminary

Low/Preliminary

Low/Preliminary

(Continued)
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Table 4. Continued

Variant
1372A>C
rs9516519

Effect on
mRNA/Protein

Drug Class

In Vitro/ In
Vivo

Antimetabolites

In vivo

Allele Effect/Association
Methotrexate: variant
associated with ↑
methotrexate levels and
toxicity in children with
acute lymphoblastic leukemia
(n = 151)85

Drug/Effect
Associationa
Low/Preliminary

a
High: annotation for a variant-drug combination where most evidence demonstrates an association. The association must be replicated in more than 1 cohort
with significant P-values. Moderate: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated
in more than 1 cohort, but there may be some studies that do not show statistical significance. Low/Preliminary: annotation for a variant-drug combination
based on a single significant study or annotation for a variant-drug combination evaluated in multiple cohorts but lacking clear evidence of an association. This
classification also encompasses associations that have been studied only in vitro.

Of particular importance to drug development is
the recent association of Jr(a–) blood group with nullallelic mutations in ABCG2.102,103 In essence, those who
have the Jr(a–) could be considered ABCG2 knockout
humans. The Jr(a–) phenotype is mainly detected in
Japanese individuals with region-dependent frequencies between 0.3% and 1.7%.103 In the Jr(a–) population, the production of anti-Jr(a) antibodies is known
to be involved in hemolytic disease, but little is known
about the effect the nonfunctional BCRP protein has
on drug disposition and efficacy. The Jr(a–) population
may aid in establishing the precise role of ABCG2 in the
pharmacokinetics of a NME.
Therefore, given the presence of common as well
as rare functional genetic variations in BCRP in the
human population, and the presence of moderate
to strong variant-drug associations, SNPs in ABCG2
should most certainly be considered as a part of the
overall drug development process for a substrate NME.

Drug Discovery and Development
Strategies
There have been a number of excellent publications in
the past 5 years, in terms of in vitro as well as in vivo
guidance for transporter-related studies during drug
discovery and development.2–10 Shown below is a very
brief 6-step summary of what should be viewed as our
opinion, with regard to drug transporters and clinically
relevant polymorphisms.

Step 1: Figure Out Extent of Metabolism vs Transport
In vitro or liver microsome studies should quickly
demonstrate the likely extent of metabolism. If the
NME is shown to be metabolically stable, anionic,
cationic, zwitterionic, or amphipathic, with a molecular
weight between 300 and 1000 daltons, transporters are
likely to be relevant in vivo.

Step 2: Transporter(s) to Screen
It is not possible to screen all the transporters. The
decision with regard to which subset of transporter
to screen should be based on therapeutic target and
likely organ(s) involved in the elimination of the NME.
For CNS-active compounds, P-gp and BCRP should
be considered. For those cleared by liver or targeting
liver, consider OATP1B1, P-gp, or BCRP. If the NME is
cleared by the kidney, particularly if the renal clearance
appears to exceed GFR, consider OAT1/3 for anionic
NMEs and OCT2 and MATE2-K for cationic NMEs
in addition to P-gp.

Step 3: OATP1B1, P-gp, and BCRP
These are the top 3 transporters to keep in mind if
a broader screening effort for various NMEs is to
be carried out earlier in the discovery process. These
transporters have shown the most clinical relevance to
date. Additional transporters might be considered later
in discovery or during development.

Step 4: Determine Transporter Inhibition–Associated DDI
Risk
There is now significant guidance with regard to in vitro
transporter studies and prediction of in vivo relevance.
In vitro inhibition data could be used as a surrogate for
loss of function polymorphism(s) in such transporters.

Step 5: If Worried About OATP1B1, P-gp, or BCRP
Polymorphisms
A number of functional SNPs in these transporters
result in loss of cell surface trafficking of the variant
transporter. Thus, instead of worrying about whether
there may be polymorphism-dependent differences in
substrate specificity, it may be easier to skip in vitro
analysis of variant transporters and directly carry out
in vivo assessment in relevant rodent knockout models.
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Table 5. Breast Cancer Resistance Protein

Variant

Effect on
mRNA/Protein

Drug Class

Select Variants and Variant Effects Within ABCG2 (BCRP)
HMG-CoA
Q141K, 421C>A
↓protein expression
reductase
rs2231142
and trafficking
inhibitors
to plasma
membrane90,91

In Vitro/In
Vivo

In vivo

In vivo
Topoisomerase
inhibitors

In vivo

In vitro
Tyrosine kinase
inhibitors

In vivo

In vitro
Anivirals

In vivo

V12M, 34G>A
rs2231137

Possible ↓
localization to
apical plasma
membrane138

Tyrosine kinase
inhibitors

In vivo

–15994C>T
rs7699188

↑ multitissue protein
expression141

Tyrosine kinase
inhibitors

In vivo

18271G>A
rs1564481

No association with
mRNA
expression38

CDK9 kinase
inhibitor

In vivo

Allele Effect/Association
Rosuvastatin: ↑ AUC in healthy
Chinese (n = 7)137 and Finnish
(n = 32)94 volunteers; superior
LDL-C lowering in Chinese
patients with
hypercholesterolemia (n =
305)96 and white patients who
had recently suffered a
myocardial infarction
(n = 601)95
Atorvastatin: ↑ AUC in healthy
Finnish (n = 32)94 volunteers
Diflomotecan: ↑ AUC and Cmax
in white cancer patients
receiving 20-minute infusion
(n = 22)97
Topotecan: ↓ efflux transport
(HEK293 cells)98
Imatinib: 5-year PFS rate in
gastrointestinal stromal tumor
patients with the AA variant
significantly superior to that of
patients with CC/CA
genotypes (n = 209)100
Imatinib: ↑ drug accumulation
(HEK293 cells)99
Raltegravir: ↓ CSF
concentrations in HIV-infected
patients (n = 14)101

Drug/Effect
Associationa

High

Moderate
Low/Preliminary

Low/Preliminary
Low/Preliminary

Low/Preliminary

Low/Preliminary
Gefitinib, Erlotinib, Icotinib: ↑
median overall survival of
Chinese advanced
non-small-cell lung cancer
patients (n = 100)139
Imatinib: homozygous wild-type
carriers showed impaired
cytogenetic response when
compared to variant carriers
(n = 229)140
Imatinib: ↑ oral clearance in
gastrointestinal stromal tumor
patients (n = 82)141
Flavopiridol: ↑ AUC and
improved response to
treatment (n = 51)142

Low/Preliminary

Low/Preliminary

a
High: annotation for a variant-drug combination where most evidence demonstrates an association. The association must be replicated in more than 1 cohort
with significant P-values. Moderate: annotation for a variant-drug combination with moderate evidence of an association. The association must be replicated
in more than 1 cohort, but there may be some studies that do not show statistical significance. Low/Preliminary: annotation for a variant-drug combination
based on a single significant study or annotation for a variant-drug combination evaluated in multiple cohorts but lacking clear evidence of an association. This
classification also encompasses associations that have been studied only in vitro.

Step 6: In Phase 1 and 2 Studies, Collect DNA and Assess
Impact on PK Relative to Transporter Genotype(s)
For NMEs that are subject to transport, having
genotype-vs-PK data as a part of the overall

development process will provide meaningful data
in terms of likely clinical impact. The key will be to
include DNA collection and genotyping strategies as
a part of the development process. Note that effect of

S54
genotype and DDI may provide additional insights
relating to the overall clinical impact because many
drugs are substrates of multiple transporters, and a
number of clinical DDI studies focus specifically on
key efflux transporters such as P-gp.

Conclusion
Predicting all the factors that can account for interpatient variation in drug response is an important goal of
the drug development process. It is now becoming clear
that genetic variations within drug transporters are
clinically relevant. Specifically, in 2014, international
statin-dosing guidelines were changed to reflect the
impact of OATP1B1 variants on statin PK profile and
toxicity. Similar to CYP enzymes, it appears that a
handful of key drug uptake and efflux transporters
account for the absorption, distribution, and elimination of the majority of currently prescribed drugs
as well as NMEs. Systematic inclusion of transporter
studies, including the consideration of polymorphisms
in relevant transporters, will result in better candidate
NME selection as well as a more robust prediction of
intersubject variation in the response to the NME when
it is released for general use.
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